These small molecules disrupt the interaction of PU.1 with its binding sites next to the promoters of target genes and lead to the downregulation of PU.1 transcriptional targets, holding a high potential as tool compounds for evaluating the role of PU.1 in neurodegenerative diseases. The gene discussed is SPI1; the disease is neurodegenerative disease.